

August 8, 2022

National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051.  
Symbol: RAINBOW

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.  
Scrip Code: 543524

**Sub: Outcome of the Board Meeting held on August 8, 2022.**

**Ref: Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations") read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015**

Dear Sir/ Madam,

In reference to the above referred provisions, please take note that the Board of Directors of Rainbow Children's Medicare Limited ("**the Company**") in their meeting held today i.e. August 8, 2022, inter-alia, considered and approved the following matters:

1. The unaudited Standalone and Consolidated Financial Results ("**Results**") of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith.
2. Convening of 24<sup>th</sup> Annual General Meeting ("**AGM**") of the Company on Thursday September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM).
3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM).

## Rainbow Children's Medicare Limited

**Registered Of ice:** 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034

**Corporate Of ice:** 8-2-19/1/a, Daulet Arcade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana - 500034

**Hyderabad:** Banjara Hills - 040 22334455 | Secunderabad - 040 42462200 | Kondapur IP - 040 42462400 |  
Kondapur OP - 040 42462100 | Hyder Nagar - 040 42462300 | LB Nagar - 040 71111333

**Vijayawada:** Currency Nagar - 0866 6669666 | Governorpet - 0866 6650250 | **Chennai:** Guindy - 044 40122444

**Bengaluru:** Marathahalli - 080 71112345 | Bannerghatta Road - 080 25512345 | Hebbal - 080 35061555

**Delhi:** Malviya Nagar - 011 66888866 | **Visakhapatnam:** Health City, Chinagadili - 0891 3501601 | Siripuram - 0891 3501555

Symbol	Type of Security	Book Closure both days inclusive	Record date	Purpose
NSE - RAINBOW BSE - 543524	Equity	Not Applicable	Thursday, September 8, 2022	1. 24 <sup>th</sup> Annual General Meeting. 2. Payment of Final Dividend, if approved at the ensuing AGM

Dividend if declared at the ensuing AGM shall be paid within a period of 30 days from the date of declaration.

4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM

The details of the reclassification of Authorised Share Capital is described below.

*"Reclassification of Authorized Share Capital from INR. 150,00,00,000 divided into (a) 13,90,55,616 Equity Shares of INR 10/- each (b) 11,46,771 - Series A 0.0001% Compulsorily Convertible Preference Shares ("Series A CCPS") of INR. 48/- each and (c) 11,33,309 Series B 0.0001% Compulsorily Convertible Preference Shares ("Series B CCPS") of INR. 48/- to INR. 150,00,00,000 divided into 15,00,00,000 Equity Shares of INR 10/- each."*

The Board Meeting commenced at 12:30 P.M. and concluded at 2:10 P.M.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

  
**Ashish Kapil**

**Company Secretary and Compliance Officer**

Encl.: As above

# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,  
Orwell, B Wing, 6<sup>th</sup> Floor, Unit-3,  
Sy No. 83/1, Plot No. 02, Raidurg,  
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000  
Fax: +91 40 7182 2399

## Limited Review Report on unaudited standalone financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

### To the Board of Directors of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited')

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') ("the Company") for the quarter ended 30 June 2022 ("the Statement").

Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2021, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company during the quarter ended 30 June 2022.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the unpublished audited year to date figures up to the third quarter of the previous financial year.



B S R & Associates LLP

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**

*Chartered Accountants*

Firm's Registration No.: 116231W/W-100024

**Jhahanwijha Shyamsukha**

*Partner*

Hyderabad

08 August 2022

Membership No.: 064550

UDIN: 22064550AOMVFB9982

Rainbow Children's Medicare Limited (formerly known as "Rainbow Children's Medicare Private Limited") CIN : 1151 CH 119811 (02/14) Incorporated Office: K-2/201 IJ/A, S11, 11 No.410, H1111 No.2, Banjar 1111, 1111d, rah 11, 11111111-50011-1 Corporate Office: X-2-11/11111111 An-had1, 1, 1111, 11 11d No.1 1 Banjar 11111111, 11111111rah 11d, 11111111ga 111-5101. -1 TIN: +91 414 9221-1, r-1111: 1011p1111 >411ar 1(11rui 1111hospitals.in				
Statement of Unaudited Statement Financial Health for the 11111111 1111d JO. 11111 2122				
Unit: In Millions rupee for the period				
Particulars	On or before 1111d		Year ended	
	30 Jun. 2022	31 March 2122	30 Jun 2021	31 March 2 22
	Unaudited 1111 for Noll' 2	Audited Hrfr Not' 3	Unaudited Refr Noll' 4	Audited
<b>INCOME</b>				
1. Revenue from operations	2,227.53	2,011.47	2,362.05	9,245.95
2. Other income	64.07	65.98	26.64	208.19
3. Total Income 11+21	2,291.60	2,077.45	2,388.69	9,454.14
<b>4. EXPENSES</b>				
a. Medical consumables and pharmacy items consumed	296.85	320.32	575.98	1,877.98
b. Employee benefits expense	287.23	298.91	235.62	1,094.12
c. Finance costs	134.29	154.86	121.91	500.05
d. Depreciation and amortisation expense	202.95	206.87	177.72	769.87
e. Professional fees to doctors	523.65	496.48	500.26	1,857.80
f. Other expenses	345.21	426.01	281.70	1,456.88
Total expenses	1,790.18	1,903.45	1,893.29	7,556.70
5. Profit before tax [3-4]	501.42	174.00	495.40	1,897.44
6. Tax expenses:				
a. Current tax	150.13	55.47	150.22	575.48
b. Deferred tax credit	(24.66)	(25.90)	(28.08)	(100.95)
Total tax expense	125.47	29.57	122.14	474.53
7. Profit for the period/year [5-6]	375.95	144.43	373.26	1,422.91
8. Other comprehensive income				
Items that will not be reclassified to profit or loss				
Remeasurement gain on defined benefit plans	6.36	3.88	1.47	13.02
Income tax relating to items that will not be reclassified to profit or loss	(1.60)	(0.98)	(0.37)	(3.28)
Other comprehensive Income for the period/year, net of tax	4.76	2.90	1.10	9.74
9. Total comprehensive Income for the period/year [7+8]	380.71	147.33	374.36	1,432.65
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.02	1,049.98	549.03	1,049.98
11. Other equity				5,312.95
12. Earning per share (Face value of Rs.10 each) (not annualised for the quarters)				
a. Basic (Rs)	3.72	1.61	4.06	15.18
b. Diluted (Rs)	3.72	1.57	3.97	14.87

## Notes :

- The stand-alone financial results for Rainbow Children's Medicare Limited (Formerly) known as Rainbow Children's Medicare Private Limited ("the Company") have been prepared in compliance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and the Companies (Indian Accounting Standards) Regulations, 2015.
- The above financial results are unaudited. The audit report of the Chartered Accountants, M/s. J. K. Mittal & Co., Chartered Accountants, dated 10th August 2022, is in conformity with the provisions of the Companies Act, 2013 and the Companies (Indian Accounting Standards) Regulations, 2015.
- The stand-alone financial results for the quarter ended 30th June 2022 are the half-yearly figures. However, the audited stand-alone financial results are not required to be audited in respect of the full previous financial year. The unpublished audited year-to-date stand-alone figures up to the third quarter of the previous financial year.
- The stand-alone figures for the quarter ended 30th June 2021 as reported in the stand-alone financial results were neither audited nor subjected to audit, however, the management has exercised its discretion to ensure that the stand-alone financial results for the period provide a true and fair view of the Company's affairs.
- During the period, the Board of Directors of the Company in their meeting held on 04 April 2022, approved conversion of (i) 1,146,771 0.0001 % Series J Compulsorily Convertible Preference Shares (CCPS) of face value of Rs. 48 each into 1,146,771 Equity Shares of Rs. 10 each and (ii) 1,133,309 0.0001% Series II Compulsorily Convertible Preference Shares of face value of INR 48 each into 1,133,309 Equity Shares of Rs. 10 each, at a conversion ratio of 1:1, on a pari passu basis with the existing Equity Shares of the Company.
- During the period, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each at the issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share). Eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity Shares, aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) i.e. 10 May 2022.

Details of utilisation of IPO proceeds:

(Rs. In Millions)

Objects of the Issue	Amount as proposed in offer document	Utilisation up to 30 June 2022	Unutilised amount as at 30 June 2022
Early redemption of NCDs issued by our Company to CDC Emer. in Markets Limited, in full	400.00	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	13.06	1,686.94
General Corporate Purposes	561.40	-	561.40
<b>Total</b>	<b>2,661.40</b>	<b>413.06</b>	<b>2,248.34</b>

Net IPO proceeds which were un-utilised as at 30 June 2022 were temporarily invested in fixed deposits with banks (held in cash and bank balances).

- Where financial results contain both consolidated and stand-alone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
- The results for the three month period ended 30 June 2022, are available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)), the National Stock Exchange of India Limited website (URL: [www.nseindia.com](http://www.nseindia.com)) and on the company's website (URL: [www.rainbowhospitals.in](http://www.rainbowhospitals.in)).

for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited

Dr. Ramesh Kancharla  
Chairman and Managing Director  
DIN: 00212270

Place : Hyderabad  
Date : 08 August 2022

# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City,  
Orwell, B Wing, 6<sup>th</sup> Floor, Unit-3,  
Sy No. 83/1, Plot No. 02, Raidurg,  
Hyderabad - 500 081 - India

Telephone: +91 40 7182 7000  
fax +91 40 7182 3000

**Limited Review Report on unaudited consolidated financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

## **To the Board of Directors of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited')**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2021, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Parent during the quarter ended 30 June 2022.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Rainbow Children's Medicare Limited (Formerly known as 'Rainbow Children's Medicare Private Limited') (Parent)

### **Subsidiaries**

- b. Rainbow Speciality Hospitals Private Limited
- c. Rosewalk Healthcare Private Limited
- d. Rainbow C R O Private Limited

## B S R & Associates LLP

- e. Rainbow Fertility Private Limited
  - f. Rainbow Children's Hospital Private Limited
  - g. Rainbow Women and Children's Hospitals Private Limited
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the unpublished audited year to date figures up to the third quarter of the previous financial year.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial results of six subsidiaries which have not been reviewed, whose interim financial results reflect total revenues of Rs. 146.95 million, total net profit after tax of Rs.11.65 million and total comprehensive income of Rs. 12.16 million, for the quarter ended 30 June 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

**For B S R & Associates LLP**

*Chartered Accountants*

Firm's Registration No.:116231W/W-100024

**Jhahanwijha Shyamsukha**

*Partner*

Hyderabad

08 August 2022

Membership No.: 064550

UDIN:22064550AOMVVM1990

Rainbow Children's Sk -dir: h - Limited (formerly, Imm, Tan, "Itainm, Child n's M'diran - Priv:td' Limited")				
CIN: 1.8511 ITCJ'1811.C112914				
It i, tin-d (Hii 11 : 8-2-120111B1, Sun 1') No. 41B, Road No.2, Bmjara Hill, 11) -rahad. 111:111:11b-SO1034				
Corporah-Ofi 11': H-2-1W/n. Ilat111'1 Ar11'ad1, 1, an', la111, Road 11111, Bmjara Hill, 11) -rahad. 11d: 11iana-S1111B4				
111: +91404W9224. 11 nr il: 1'Q11J11 H tn -ar -uTai1111c 111'1il:11111				
111-111-11 of 1'1111111111 ('O11 olitak d Finan11ial 111'111 for tht q11111'r t11k d )0 Jun, 2022				
(H. 1111111111) 1111111111 1111111111				
Particulars	Q 11111'r 11111d			Year ended
	31,1111' 2112	31 111'd, 2112	30,111' 2111	31 111'd, 211 2
	111111111d 1111111 Null' 2	111111111 1111111 Null' 3	111111111d 1111111 Null' 4	111111111d
<b>INCOME:</b>				
1. Revenue from operations	21 71.52	2124.47	2463.57	9,737.58
2. Other income	60.33	(11.86)	21.35	181.7
<b>3 Total income' 11+21</b>	<b>2,431.85</b>	<b>2,186.33</b>	<b>2,484.92</b>	<b>9,926.95</b>
<b>4 EXPENSES</b>				
a. Medical consumables and pharmacy items consumed	318.02	337.61	588.30	1,947.29
b. Employee benefits expense	305.38	317.13	251.47	1,160.71
c. Finance costs	142.16	162.78	129.98	532.03
d. Depreciation and amortisation expense	219.12	222.82	193.13	832.63
e. Professional fees to doctors	562.12	535.36	544.88	2,037.60
f. Other expenses	365.09	453.04	296.28	1,543.23
<b>Total expenses</b>	<b>1,911.89</b>	<b>2,028.74</b>	<b>2,004.04</b>	<b>8,053.49</b>
<b>5. Profit before tax [3-4]</b>	<b>519.96</b>	<b>157.59</b>	<b>480.88</b>	<b>1,873.46</b>
<b>6. Tax expenses:</b>				
a. Current tax	156.40	55.62	150.43	576.13
b. Deferred tax credit	(24.05)	(20.63)	(28.35)	(89.40)
<b>Total tax expense</b>	<b>132.35</b>	<b>34.99</b>	<b>122.08</b>	<b>486.73</b>
<b>7. Profit for the period/year [5-6]</b>	<b>387.61</b>	<b>122.60</b>	<b>358.80</b>	<b>1,386.73</b>
<b>8. Other comprehensive income</b>				
<i>Items that will not be reclassified to profit or loss</i>				
Re-measurement gain On defined benefit plans	6.93	4.19	1.61	13.63
Income tax relating to re-measurement gain on defined benefit plans	(1.65)	(1.02)	(0.39)	(3.36)
<b>Other comprehensive income for the period/year, net of tax</b>	<b>5.28</b>	<b>3.17</b>	<b>1.22</b>	<b>10.27</b>
<b>9. Total comprehensive income for the period/year [7+8]</b>	<b>392.89</b>	<b>125.77</b>	<b>360.02</b>	<b>1,397.00</b>
<b>Profit for the period/year attributable to:</b>				
Owners of the Company	381.89	121.94	359.33	1,382.66
Non-controlling interests	5.72	0.66	(0.53)	4.07
<b>Profit for the period/year</b>	<b>387.61</b>	<b>122.60</b>	<b>358.80</b>	<b>1,386.73</b>
<b>Other comprehensive income for the period/year attributable to:</b>				
Owners of the Company	5.28	3.17	1.22	10.23
Non-controlling interests	0.03	0.02	0.01	0.04
<b>Other comprehensive income for the period/year</b>	<b>5.28</b>	<b>3.17</b>	<b>1.22</b>	<b>10.27</b>
<b>Total comprehensive income for the period/year attributable to:</b>				
Owners of the Company	387.14	125.09	360.54	1,392.89
Non-controlling interests	5.75	0.68	(0.52)	4.11
<b>Total comprehensive income for the period/year</b>	<b>392.89</b>	<b>125.77</b>	<b>360.02</b>	<b>1,397.00</b>
<b>10. Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>1,015.02</b>	<b>1,049.98</b>	<b>549.03</b>	<b>1,049.98</b>
<b>11. Other equity</b>				<b>4,978.06</b>
<b>12. Earning per share (Face value of Rs.10 each) (not annualised for the quarters)</b>				
- Basic (Rs)	3.78	1.36	3.91	14.75
- Diluted (Rs)	3.78	1.33	3.82	14.45

## Notes :

- The consolidated financial results of Rainbow Children's Medicare Limited (formerly known as Rainbow Children's Medicare Private Limited) ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  - The above consolidated financial results for the quarter ended 30 June 2022 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08 August 2022.
  - The consolidated figures for the quarter ended 31 March 2022 are the balancing figures between the audited consolidated figures in respect of the full previous financial year and the unpublished audited year to date consolidated figures upto the third quarter of the previous financial year.
  - The consolidated figures for the quarter ended 30 June 2021 as reported in these consolidated financial results were neither reviewed nor subject to audit, however, the management has exercised necessary due diligence to ensure that the consolidated financial results for these period provide a true and fair view of the Company's affairs.
  - During the period, the Board of Directors, at their meeting held on 04 April 2022, approved conversion of (i) 1,146,771 0.0001% Series A Compulsorily Convertible Preference Shares ("CPS") of face value of Rs. 48 each into 1,146,771 Equity Shares of Rs. 10 each and (ii) 1,133,309 0.0001% Series B Compulsorily Convertible Preference Shares of face value of INR 48 each into 1,133,309 Equity Shares of Rs. 10 each, at a conversion ratio of 1:1, ratio being pari passu with the existing Equity Shares of the Company.
  - During the period, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees holding in the employee's reservation portion were allocated a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f. 10 May 2022.
- The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between company and selling shareholders as per the respective of size) from proceeds of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted to securities premium.

### Details of utilisation of IPO proceeds

(Rs In Millions)

Objects of the Issue	Amount as proposed In offer document	Utilisation up to 30 June 2022	Unutilised amount as at 30 June 2022
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	13.06	1,686.94
General Corporate Purposes	561.40	-	561.40
Total	2,661.40	413.06	2,248.34

Net IPO proceeds which were unutilised as at 30 June 2022 were temporarily invested in fixed deposits with banks (held in cash and bank balances).

- The results for the three month period ended 30 June 2022, are available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)), the National Stock Exchange of India Limited website (URL: [www.nseindia.com](http://www.nseindia.com)) and on the company's website (URL: [www.rainbowhospitals.in](http://www.rainbowhospitals.in)).
- The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- The consolidated financial results include the financial results of Rainbow Children's Medicare Limited (parent company) and the financial results of its subsidiaries, Rainbow CRO Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited and Rainbow Children's Hospital Private Limited (together called as the "Group").

for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla  
Chairman and Managing Director  
DIN: 00212270